Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Appetite|November 1, 2006
Chocolate craving among children: implications for disordered eating patternsFiona Cartwright, Werner G K Stritzke, Kevin Durkin, et al.
International Journal of Pediatric Obesity : IJPO : an Official Journal of the International Association for the Study of Obesity|October 2, 2007
Television, computer use, physical activity, diet and fatness in Australian adolescentsValerie Burke, Lawrie J Beilin, Kevin Durkin, et al.
European Journal of Human Genetics : EJHG|February 13, 2014
Homozygous microdeletion of exon 5 in ZNF277 in a girl with specific language impairmentFabiola Ceroni, Nuala H Simpson, Clyde Francks, et al.
Developmental Medicine and Child Neurology|October 15, 2013
Increased prevalence of sex chromosome aneuploidies in specific language impairment and dyslexiaNuala H Simpson, Laura Addis, William M Brandler, et al.
Plos Genetics|March 18, 2015
Exome sequencing in an admixed isolated population indicates NFXL1 variants confer a risk for specific language impairmentPía Villanueva, Ron Nudel, Alexander Hoischen, et al.
American Journal of Human Genetics|August 4, 2009
CMIP and ATP2C2 modulate phonological short-term memory in language impairmentDianne F Newbury, Laura Winchester, Laura Addis, et al.
The Lancet. Psychiatry|October 17, 2018
The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trialBill Deakin, John Suckling, Thomas R E Barnes, et al.
The Journal of Antimicrobial Chemotherapy|June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Pageof 13